- Home
- SCLX
as 12-11-2024 4:00pm EST
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 81.7M | IPO Year: | N/A |
| Target Price: | $11.33 | AVG Volume (30 days): | 184.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $2.63 | Next Earning Date: | 12-24-2024 |
| Revenue: | $50,833,000 | Revenue Growth: | 9.41% |
| Revenue Growth (this year): | 32.77% | Revenue Growth (next year): | 50.71% |
Latest Scilex Holding Company News
SCLX Breaking Stock News: Dive into SCLX Ticker-Specific Updates for Smart Investing
MT Newswires
11 hours ago
Scilex Holding Venture Initiates Trial Enrollment for Alzheimer's Treatment
GlobeNewswire
12 hours ago
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025
GlobeNewswire
17 hours ago
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor
Argus Research
18 hours ago
Daily – Vickers Top Insider Picks for 12/11/2024
Zacks Small Cap Research
2 days ago
SCLX Gets Exclusive Rights to Important Drug
GlobeNewswire
2 days ago
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases
GlobeNewswire
2 days ago
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 12/10/2024
Compare SCLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCLX Scilex Holding Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.